Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × elesclomol × Clear all
NCT00084214 2014-03-06

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
103 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00088088 2008-12-04

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
86 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡